Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Clinical trial NCT03759184 · TERMINATED
Trial details
- NCT number
- NCT03759184
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-11
- Primary completion
- 2019-12-15
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.